The global microarrays market was valued at USD 1.65 billion in 2025. The market is projected to grow from USD 1.76 billion in 2026 to USD 2.98 billion by 2034, exhibiting a compound annual growth rate of 6.8% during the forecast period. Contrive Datum Insights presents this information in its report titled "Microarrays Market Size, Share & Industry Analysis, By Type (DNA Microarrays, MM Chips, Protein Microarrays, Peptide Microarrays, Tissue Microarrays, Cellular Microarrays, Other), Product (Consumables, Instruments, Software and services), End-use (Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Other End Users), Application (Drug Discovery, Diagnostics, Genomic, Proteomics, Other), Technology (Spotted Microarrays, In-situ Synthesized Microarrays, Electrochemical Microarrays), and Regional Forecast, 2026-2034".
Microarrays are solid-support platforms, typically glass slides, silicon chips or bead-based formats, that hold thousands of immobilized DNA, protein or peptide probes arranged in a fixed grid to allow parallel detection of genetic or protein targets in a single sample. They are used to profile gene expression, genotype variants, screen protein interactions and support companion diagnostic panels. Buyers include pharmaceutical and biotechnology companies conducting drug discovery research, academic and government research institutes, and diagnostic laboratories running hereditary, oncology or infectious disease panels.
Rising adoption of companion diagnostics and precision medicine testing
Rising adoption of companion diagnostics and precision medicine testing is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 6.8% a year, the type lines exposed to it move fastest: Tissue Microarrays compounds at 8.56%, taking its share of revenue from 7.88% to 9.06% and its value from USD 0.13 billion to USD 0.27 billion.
The study also runs a bull case: diagnostic panel adoption and proteomics research funding both expand faster than the base case assumes, and sequencing displacement of genotyping applications stays contained to its current pace. That path ends 2034 at USD 3.4 billion, above the USD 2.98 billion base case.
On the downside, sequencing platforms displace genotyping applications faster than modeled and research funding growth slows in the largest academic markets, compressing consumable pull-through across the forecast period, which would hold 2034 revenue to USD 2.56 billion. DNA Microarrays, which carries 37.58% of 2025 revenue, already grows at only 5.46% against the market's 6.8%, so the largest part of the base is also its slowest.
The Competitive Split Runs by Type
Two positions matter, and they are set by type. DNA Microarrays carries 37.58% of 2025 revenue (USD 0.62 billion) and is still the largest line in 2034 at 33.89%, hard to take from an incumbent. Tissue Microarrays, at 8.56%, is where the USD 1.65 billion base is redistributed. The two demand different capabilities.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Product | Consumables | 58.18% · USD 0.96 billion | Software and services 10.22% |
| End-use | Research & Academic Institutes | 40% · USD 0.66 billion | Diagnostic Laboratories 8.59% |
| Application | Drug Discovery | 32.12% · USD 0.53 billion | Proteomics 9.25% |
| Technology | Spotted Microarrays | 44.85% · USD 0.74 billion | Electrochemical Microarrays 9.06% |
- Regionally, the lead sits with North America: 41.9% of 2025 global revenue, USD 0.69 billion rising to USD 1.13 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 22.9% in 2025 to 28% in 2034, with revenue growing from USD 0.38 billion to USD 0.83 billion.
- Middle East and Africa remains the smallest region throughout, at 3.7% of 2025 revenue and 4% by 2034.
- DNA Microarrays was the leading type line in 2025, taking 37.58% of revenue at USD 0.62 billion.
- No type line grows faster than Tissue Microarrays, at a projected 8.56%.
- The United States is the largest single country market at USD 0.61 billion in 2025, 36.97% of global revenue.
The report segments the market across five axes; by type, and by product, end-use, application and technology; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 2.56 billion and USD 3.4 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.